Goldman Sachs Group set a €63.00 ($73.26) target price on Lanxess (ETR:LXS) in a report published on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Other analysts also recently issued reports about the company. Nord/LB set a €62.00 ($72.09) price target on Lanxess and gave the company a buy rating in a report on Thursday, January 24th. Warburg Research set a €66.80 ($77.67) price target on Lanxess and gave the company a buy rating in a report on Monday, February 11th. JPMorgan Chase & Co. set a €55.00 ($63.95) price target on Lanxess and gave the company a buy rating in a report on Thursday, March 14th. Commerzbank set a €64.00 ($74.42) price target on Lanxess and gave the company a buy rating in a report on Tuesday, March 5th. Finally, HSBC set a €80.00 ($93.02) price objective on shares of Lanxess and gave the company a buy rating in a research report on Wednesday, March 20th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of €61.72 ($71.76).
Shares of ETR LXS opened at €47.38 ($55.09) on Thursday. Lanxess has a 12-month low of €39.47 ($45.90) and a 12-month high of €72.60 ($84.42). The firm has a market capitalization of $4.20 billion and a P/E ratio of 10.32. The company has a debt-to-equity ratio of 101.71, a current ratio of 2.61 and a quick ratio of 1.53.
LANXESS Aktiengesellschaft, a specialty chemicals company, develops, manufactures, and markets chemical intermediates, specialty chemicals, and plastics worldwide. It operates in five segments: Advanced Intermediates, Specialty Additives, Performance Chemicals, Engineering Materials, and ARLANXEO. The Advanced Intermediates segment offers high-grade intermediates for the agrochemical and coating industries; fine chemicals as precursors and intermediates for the pharmaceutical, agrochemical, and specialty chemical industries; customer-specific specialties; organometallics; and tire chemicals.
Read More: What is the downside to momentum investing?
Receive News & Ratings for Lanxess Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lanxess and related companies with MarketBeat.com's FREE daily email newsletter.